

Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis

Technical Report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis



The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member Countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective - the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. An annual subscription to this series, comprising four to six such reports, costs CHF 150.00/US\$ 180.00 (CHF 105.00/US\$ 126.00 in developing countries). For further information, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int; order on line: http://www.who.int/bookorders).

Research Priorities for Chagas Disease, Human African Trypanosomiasis and Leishmaniasis

Technical Report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization



WHO Library Cataloguing-in-Publication Data

Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis.

(Technical report series ; no. 975)

1. Chagas disease. 2. Trypanosomiasis, African. 3. Leishmaniasis. 4. Research. 5. Neglected diseases. 6. Poverty. 7. Developing countries. I.World Health Organization. II.TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. III.Series.

ISBN 978 92 4 120975 5 ISSN 0512-3054 (NLM classification: WC 695)

© World Health Organization 2012

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Printed in Italy

Contents

| WHO/TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis v | | | | | | | |
|---|---|--|--|--|--|--|--|
| Ab | brevi | ations and acronyms | vii | | | | |
| Ex | ecutiv | ve summary | xi | | | | |
| 1. | Introduction | | | | | | |
| | Reasons for setting research priorities TDR stewardship mandate Goal of this report /strategic objectives Overview | | | | | | |
| 2. | Methodology and prioritization | | | | | | |
| | 2.1 2.2 2.3 | Authoritative evidence review to define thematic areas Stakeholders' consultation and second round of criteria-based ranking Final round of ranking | | | | | |
| 3. | Epid 3.1 3.2 3.3 | 2 Human African trypanosomiasis | | | | | |
| 4. | Clinical forms, pathogenesis and HIV coinfection | | | | | | |
| | 4.1 4.2 4.3 | Chagas disease 4.1.1 Clinical presentations 4.1.2 Chagas heart disease 4.1.3 Gastrointestinal manifestations 4.1.4 Congenital Chagas disease 4.1.5 Chagas disease and HIV coinfection Human African trypanosomiasis 4.2.1 Pathogenesis 4.2.2 Clinical presentation Leishmaniasis 4.3.1 Clinical presentations | 21 21 23 23 23 24 24 24 24 24 26 26 | | | | |
| 5. | Diagnosis | | | | | | |
| | 5.1 | Chagas disease 5.1.1 Parasitological diagnosis 5.1.2 Serology 5.1.3 Quantitative and qualitative detection of parasite DNA 5.1.4 Diagnosis in newborns 5.1.5 Diagnosis of therapy efficacy and cure 5.1.6 Diagnosis of drug resistant Chagas disease Human African trypanosomiasis 5.2.1 Demonstration of parasite 5.2.2 Serology 5.2.3 Quantitative and qualitative detection of parasite DNA | 31 31 31 34 34 35 35 35 35 35 35 38 | | | | |
| | | 5.2.4 Staging of the disease | 38 | | | | |

iii

| | 5.3 | Leishr | naniasis | 38 | | | |
|---------------------------------------|---|----------------|---|----------|--|--|--|
| | | 5.3.1 | Parasitological diagnosis | 38 | | | |
| | | 5.3.2 | Serology | 40 | | | |
| | | 5.3.3 | Detection of parasite products | 41 | | | |
| | | 5.3.4 | Quantitative and qualitative detection of parasite DNA | 41 | | | |
| 6. | Drug | js and | drug resistance | 43 | | | |
| | 6.1 | Currei | nt treatment and development of new drugs | 47 | | | |
| | | 6.1.1 | Chagas disease | 47 | | | |
| | | 6.1.2 | Human African trypanosomiasis | 49 | | | |
| | | 6.1.3 | Leishmaniasis | 50 | | | |
| 7. | Vaccines against Chagas disease, human African trypanosomiasis and leishmaniasis | | | | | | |
| | and | leishn | naniasis | 55 | | | |
| | 7.1 | Overv | iew | 55 | | | |
| | 7.2 | Chaga | as disease | 55 | | | |
| | | | n African trypanosomiasis | 58 | | | |
| | 7.4 | Leishr | naniasis | 59 | | | |
| 8. | Vector control | | | | | | |
| | 8.1 | Chaga | is disease: triatomine bug control | 63 | | | |
| | 8.2 | Huma | n African trypanosomiasis: tsetse fly control | 64 | | | |
| | | 8.2.1 | Tsetse species of highest priority | 65 | | | |
| | | 8.2.2 | Control activities at all levels | 66 | | | |
| | | | Costs of vector control | 67 | | | |
| | 8.3 | | naniasis: sandfly control | 67 | | | |
| | | | Source reduction | 67 | | | |
| | | 8.3.2 | Targeting sugar-feeding adult sandflies | 72 | | | |
| | | 8.3.3 | Extermination of sandflies feeding on domestic animals | 72 73 | | | |
| | | 8.3.4 8.3.5 | Flight barriers for preventing sandflies from reaching houses Protection of homes – indoor residual insecticide spraying | 73 | | | |
| | | 8.3.6 | Protection of rooms/porches – insecticide diffusers and coils | 74 | | | |
| | | 8.3.7 | Personal protection – insecticide-treated nets and repellents | 74 | | | |
| | | 8.3.8 | Integrated disease-control campaigns | 75 | | | |
| 9. | Econ | omic | evaluation of health-care interventions | 77 | | | |
| | | | | 81 | | | |
| 10. Research priority recommendations | | | | | | | |
| Acknowledgements | | | | | | | |
| References | | | | | | | |
| Ap | Appendices | | | | | | |

WHO/TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis (DRG3) 2009–2010

Members

Professor M. Barrett, University of Glasgow, Glasgow Scotland

- Professor M. Boelaert, Institute of Tropical Medicine, Epidemiology and Disease Control Unit, Antwerp, Belgium
- Ms M. Castillo-Riquelme, Health Economics Consultant, Ministerio de Salud, Departamento de Economía de la Salud, Ministry of Health, Chile
- Professor M.J. Lehane, Liverpool School of Tropical Medicine, Liverpool, England
- Professor P. Lutumba, Institut National de Recherche Bio-Médicale, Kinshasa University, Kinshasa, Democratic Republic of Congo
- Professor E. Matovu, College of Veterinary Medicine, Animal Resources and Biosecurity, Makerere University, Kampala, Uganda
- Professor M.M. Mukhtar, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan (*co-Chair*)
- Dr D. Sacks, Head, Intracellular Parasite Biology Section, Laboratory of Parasitic Diseases, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Bethesda MD, USA
- Professor C. Schofield, Coordinator, Latin American Network for Research on the Biology and Control of Triatominae (ECLAT), Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, England
- Dr S.A. Sosa-Estani, Director, National Institute of Parasitology, ANLIS Malbrán, Ministerio de Salud, Argentina
- Professor K. Stuart, Founder, Seattle Biomedical Research Institute, Seattle, WA, USA (Chair)
- Professor S. Sundar, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India
- Professor A. Warburg, Faculty of Medicine, Hebrew University, Einkerem, Israel
- Professor B. Zingales, Instituto de Quimica, Universidade de São Paulo, Sao Paulo, Brazil (co-Chair)

Career Development Fellow

Dr S. Bakhiet, Institute of Endemic Diseases, University of Khartoum, Sudan

Secretariat

Dr D. Kioy, Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland (*Secretary*)

Research Priorities for Chagas Disease, HAT and Leishmaniasis Report of the TDR Disease Reference Group

- Dr A.M.J Oduola, Coordinator, Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland
- Dr Michael Wilson, Scientist, Special Programme for Research and Training in Tropical Diseases, WHO, Geneva, Switzerland

